¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå : Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² ¹× ¿¹Ãø(2024-2032³â)
Xenotransplantation Market, By Product, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1477115
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 289 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,592,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,570,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,983,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ÀÇ ÁÖ¿ä ³»¿ë

ÀÌÁ¾ ÀÌ½Ä ½ÃÀå ±Ô¸ð´Â 2023³â 133¾ï 510¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 10.2%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌÁ¾ ÀÌ½Ä ½ÃÀå - ½ÃÀå ¿ªÇÐ

Á¶Á÷ ¹× Àå±â À̽Ŀ¡ ´ëÇÑ ¼ö¿ä Áõ°¡

ÀÌÁ¾ À̽ÄÀº À̽ÄÀ» À§ÇÑ Àå±â ¹× Á¶Á÷ÀÇ ´ëü °ø±Þ¿øÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. À̽Ŀë ÀÎü Àå±â ¹× Á¶Á÷ÀÇ ºÎÁ·À¸·Î ÀÎÇØ À̽ÄÀÌ ÇÊ¿äÇÑ È¯ÀÚµéÀÇ ±ä ´ë±âÀÚ ¸í´Ü°ú ³ôÀº »ç¸Á·ü·Î À̾îÁø´Ù´Â Á¡À» °¨¾ÈÇÒ ¶§ À̴ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. ÀÌÁ¾ ÀÌ½Ä ±â¼ú °³¹ß¿¡´Â ¸¹Àº ¿¬±¸¿Í Çõ½ÅÀÌ ÇÊ¿äÇϸç, ÀÌ´Â ´Ù¸¥ ÀÇÇÐ ºÐ¾ßÀÇ ¹ßÀüÀ¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)´Â ÀÌÁ¾ À̽Ŀ¡´Â ÀÌ½ÄÆí ¼¼Æ÷¿Í Á¶Á÷¿¡ ÀÇÇÑ °¨¿°ÀÇ ÀáÀçÀû À§ÇèÀÌ Àֱ⠶§¹®¿¡ ±âÁõÀÚ ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ±ÔÁ¦¸¦ ±ÔÁ¤Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇèÀÌ ¾ø±â ¶§¹®¿¡ ±× À§ÇèÀÇ Á¤µµ¸¦ ¾Ë ¼ö ¾ø½À´Ï´Ù.

ÀÌÁ¾ ÀÌ½Ä ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ¸Å³â ¾à 10.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¿ëµµº°·Î´Â Àå±â À̽ÄÀÌ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµÆ½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î´Â º´¿ø ¹× Ŭ¸®´ÐÀÌ 2023³â ÁÖ¿ä À¯ÇüÀ¸·Î ²ÅÇû½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ¸·Î ºÎ»óÇß½À´Ï´Ù.

ÀÌÁ¾ ÀÌ½Ä ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°è ÀÌÁ¾ ÀÌ½Ä ½ÃÀåÀº Á¦Ç°, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

ÀÌÁ¾ À̽ÄÀº ÇÑ Á¾¿¡¼­ ´Ù¸¥ Á¾À¸·Î Àå±â³ª Á¶Á÷À» À̽ÄÇÏ´Â °úÁ¤À¸·Î, À̽Ŀë Àΰ£ Àå±âÀÇ ½É°¢ÇÑ ºÎÁ·¿¡ ´ëóÇÒ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌÁ¾ À̽ÄÀº Àå±âÀÇ ´ëü °ø±Þ¿øÀ» Á¦°øÇϰí, ºÎÁ·Çϱ⠽¬¿î À̽Ŀë Àΰ£ Àå±â¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ ½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚº°·Î ´ÙÀ½°ú °°Àº ¼¼ °¡Áö ¹üÁÖ·Î ºÐ·ùµÈ´Ù: ÀÌÁ¾ À̽ÄÀº ÇØºÎÇÐÀûÀ¸·Î³ª »ý¸®ÇÐÀûÀ¸·Î Àΰ£°ú À¯»çÇÑ µÅÁö¿Í °°Àº µ¿¹°ÀÇ Àå±â¸¦ »ç¿ëÇÏ¿© À̽ÄÀ» À§ÇÑ Àΰ£ Àå±âÀÇ ºÎÁ·À» ÇØ°áÇÒ ¼ö ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ Àå±â À̽ÄÀ» ±â´Ù¸®´Â ȯÀÚÀÇ »ý¸íÀ» ±¸ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌÁ¾ À̽ÄÀº Á¶Á÷ Àç»ý ¹× º¹±¸¸¦ À§ÇÑ »ý¹°ÇÐÀû ¹ßÆÇÀ̳ª ¸ÅÆ®¸¯½º¸¦ ¸¸µå´Â Á¶Á÷ °øÇп¡µµ Ȱ¿ëµÉ ¼ö ÀÖ½À´Ï´Ù.

ÀÌÁ¾ ÀÌ½Ä ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®

ºÏ¹ÌÁö¿ªÀº ÀÇ·áºÐ¾ßÀÇ ¹ßÀü°ú Àå±âºÎÀü ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌÁ¾ÀÌ½Ä ½ÃÀå¿¡¼­ ¼±µµÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ±âÁ¸ ÀÎÇÁ¶ó, ¿¬±¸ ±â¼ú, ÀÇ·á¿¡ ´ëÇÑ ÅõÀÚ·Î ÀÎÇØ ÀÌÁ¾ À̽İú °°Àº ÷´Ü ÀÇ·á ±â¼úÀÇ °³¹ß ¹× Àû¿ë¿¡ ÀÖ¾î ÁÖµµ±ÇÀ» Áã°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àα¸ Áõ°¡·Î ÀÎÇØ ÀÇ·á ¼­ºñ½º, ƯÈ÷ ÀÌÁ¾ À̽Ŀ¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀÌÁ¾ ÀÌ½Ä ½ÃÀå - °æÀï ±¸µµ:

ÀÌÁ¾ ÀÌ½Ä ½ÃÀå¿¡´Â »ý¸í°øÇÐ ±â¾÷, Á¦¾à ±â¾÷, Çмú ±â°ü, ¿¬±¸ ±â°ü µî ´Ù¾çÇÑ ±â¾÷ÀÌ ÁøÃâÇØ ÀÖ½À´Ï´Ù. ±× Áß¿¡´Â Preservation Solutions, OrganOX Limited, B. Braun Medical Institute, Terumo Medical Corporation, Roche, Astellas Pharma, Sino-Clone Organ Biotechnology µîÀÇ ÁÖ¿ä ±â¾÷µéÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Genesis´Â À¯ÀüÀÚ ÆíÁý ±â¼úÀ» ÀÌ¿ëÇÑ ÀÌÁ¾ÀÌ½Ä ¼Ö·ç¼Ç °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ´Â »ý¸í°øÇÐ ±â¾÷ÀÔ´Ï´Ù. µÅÁö Àå±â¸¦ Àΰ£¿¡°Ô ÀûÇÕÇϵµ·Ï À¯ÀüÀÚ ÀçÁ¶ÇÕÀ» ÇÏ´Â °ÍÀ¸·Î À¯¸íÇÕ´Ï´Ù. ÀÌµé ±â¾÷Àº ÀÌÁ¾ ÀÌ½Ä ±â¼úÀ» ¹ßÀü½ÃŰ°í ½ÃÀå¿¡ Ãâ½ÃÇϱâ À§ÇÑ ¿¬±¸, °³¹ß ¹× »ó¾÷È­ ³ë·Â¿¡ Àû±ØÀûÀ¸·Î Âü¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 3¿ù ¸Å»çÃß¼¼Ã÷ Á¾ÇÕº´¿ø¿¡¼­ ¼¼°è ÃÖÃÊ·Î »ì¾ÆÀִ ȯÀÚ¿¡°Ô À¯ÀüÀÚ º¯Çü µÅÁöÀÇ ½ÅÀåÀ» À̽ÄÇÑ »ç·Ê°¡ ÀÖ¾ú½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÀÌÁ¾ ÀÌ½Ä ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀÌÁ¾ ÀÌ½Ä ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ÀÌÁ¾ ÀÌ½Ä »ê¾÷ ¿¬±¸

Á¦5Àå ÀÌÁ¾ ÀÌ½Ä ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ÀÌÁ¾ ÀÌ½Ä ½ÃÀå ±¸µµ

Á¦7Àå ÀÌÁ¾ ÀÌ½Ä ½ÃÀå - Á¦Ç°º°

Á¦8Àå ÀÌÁ¾ ÀÌ½Ä ½ÃÀå - ¿ëµµº°

Á¦9Àå ÀÌÁ¾ ÀÌ½Ä ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ÀÌÁ¾ ÀÌ½Ä ½ÃÀå - Áö¿ª

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - ÀÌÁ¾ ÀÌ½Ä ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Xenotransplantation Market size was valued at USD 13,305.1 Million in 2023, expanding at a CAGR of 10.2% from 2024 to 2032.

Xenotransplantation is the process of transplanting living cells, tissues, or organs from one species to another. It typically refers to transplanting organs or tissues from animals into humans. The rising incidence of organ failure due to factors like aging populations, lifestyle diseases, and chronic conditions increases the demand for alternative transplant options. However, the risk of immune rejection and transmission of infectious diseases from the donor animal to the recipient poses significant challenges to the widespread adoption of xenotransplantation. Moreover, advances in gene editing technologies like CRISPR/Cas9 offer opportunities to address immunological barriers and potentially expanding the pool of transplantable organs.

Xenotransplantation Market- Market Dynamics

Increasing need for tissue and organ transplantation

Xenotransplantation could potentially provide an alternative source of organs and tissues for transplantation, thereby expanding the supply beyond what is available from human donors. This is particularly important given the shortage of human organs and tissues for transplantation, leading to long waiting lists and high mortality rates for patients in need. The development of xenotransplantation technologies requires significant research and innovation, which can also lead to advancements in other areas of medicine. World Health Organization (WHO) have set regulations for clinical trials of a donor as xenotransplantation carries the potential risk of the transmission of infection with the cells or tissues of the graft. The degree of risk is unknown in the absence of clinical trials.

Xenotransplantation Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.2% over the forecast period (2024-2032)

Based on application segmentation, organ transplantation was predicted to show maximum market share in the year 2023

Based on end users segmentation, hospitals & clinics was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Xenotransplantation Market- Segmentation Analysis:

The Global Xenotransplantation Market is segmented on the basis of Product, Application, End User, and Region.

The market is divided into five categories based on application: Xenotransplantation, the process of transplanting organs or tissues from one species to another, has the potential to address the critical shortage of human organs for transplantation. Xenotransplantation could provide an alternative source of organs, reducing the dependency on human donors, which are often in short supply.

The market is categorized into three categories based on end user: : Xenotransplantation could address the shortage of human organs for transplantation by using organs from animals, such as pigs, which have anatomical and physiological similarities to humans. This could potentially save the lives of patients awaiting organ transplants. Xenotransplantation can be used in tissue engineering to create biological scaffolds or matrices for tissue regeneration and repair.

Xenotransplantation Market- Geographical Insights

North America's strong progress in the medical field and the growing number of organ failure cases contribute to the region's leadership in the xenotransplantation market. The region is equipped to take the lead in the development and application of cutting-edge medical technologies like xenotransplantation because of its existing infrastructure, research skills, and healthcare investments. Additionally, the growing population in the Asia-Pacific region raises the need for healthcare services, particularly xenotransplantation.

Xenotransplantation Market- Competitive Landscape:

Xenotransplantation market involves various players including biotechnology companies, pharmaceutical companies, academic institutions, and research organizations. Several of the leading companies in the "Global Xenotransplantation Market" are included in it, including Preservation Solutions, OrganOX Limited, B. Braun Medical Institute, Terumo Medical Corporation, Roche, Astellas Pharma, and Sino-Clone Organ Biotechnology. For instance, eGenesis is a biotechnology company focused on using gene editing technologies to develop xenotransplantation solutions. They are known for their work in genetically modifying pigs to make their organs more compatible with humans. These companies are actively involved in research, development, and commercialization efforts to advance xenotransplantation technologies and bring them to market. For instance, in March 2024, world's first genetically-edited pig kidney transplant into living recipient performed at massachusetts general hospital.

Recent Developments:

In April 2024, United Therapeutics Corporation, a public benefit corporation, announced the world's first successful transplant of a UThymoKidney, which the company produced, into a living person. This transplant represents several historic firsts for transplantation:

In March 2023, Johns Hopkins Medicine received $21.4 million to advance viability of animal organs for transplants and enable human clinical trials.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL XENOTRANSPLANTATION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Terumo Medical Corporation

Transonic

F. Hoffmann-La Roche Ltd.

Astellas Pharma, Inc.

Preservation Solutions, Inc.

OrganOX Limited

Bio Med Pvt. Ltd.

Transplant Biomedical

TransMedic, Pte. Ltd.

Novartis AG

Organ Recovery Systems

Accord Healthcare

Pfizer, Inc

Veloxis Pharmaceuticals, Inc.

Others

GLOBAL XENOTRANSPLANTATION MARKET, BY PRODUCT - MARKET ANALYSIS, 2019 - 2032

GLOBAL XENOTRANSPLANTATION MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL XENOTRANSPLANTATION MARKET, BY END USER - MARKET ANALYSIS, 2019 - 2032

GLOBAL XENOTRANSPLANTATION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Xenotransplantation Market Overview

2. Executive Summary

3. Xenotransplantation Key Market Trends

4. Xenotransplantation Industry Study

5. Xenotransplantation Market: COVID-19 Impact Analysis

6. Xenotransplantation Market Landscape

7. Xenotransplantation Market - By Product

8. Xenotransplantation Market - By Application

9. Xenotransplantation Market - By End User

10. Xenotransplantation Market- By Geography

11. Key Vendor Analysis- Xenotransplantation Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â